Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease.
Friese
G
G
Discher
T
T
Füssle
R
R
Schmalreck
A
A
Lohmeyer
J
J
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000382:microbiology* / Q000517:prevention & control; D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002825:Chorioretinitis / Q000188:drug therapy; D003453:Cryptococcosis / Q000188:drug therapy / Q000382:microbiology* / Q000517:prevention & control; D003455:Cryptococcus neoformans / Q000187:drug effects / Q000302:isolation & purification; D026141:Drug Resistance, Multiple, Fungal; D015725:Fluconazole / Q000494:pharmacology / Q000627:therapeutic use*; D005437:Flucytosine / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D017964:Itraconazole / Q000494:pharmacology / Q000627:therapeutic use*; D016919:Meningitis, Cryptococcal / Q000188:drug therapy / Q000382:microbiology* / Q000517:prevention & control; D011014:Pneumonia / Q000188:drug therapy / Q000382:microbiology; D011239:Prednisolone / Q000494:pharmacology / Q000627:therapeutic use; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use*; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D017964:Itraconazole; D000666:Amphotericin B; D015725:Fluconazole; D011239:Prednisolone; D005437:Flucytosine; D065819:Voriconazole